# US 2024/0254155 A1 · Novel compound isolated from spinach, and composition comprising same for preventing or treating inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254155 A1
- Document ID: US20240254155A1
- Status: Published application
- Kind: A1
- Application number: 18/564,361
- Filed: 2022-05-04
- Published: 2024-08-01
- Earliest claimed: 2021-05-27
- Assignees: Korea Research Institute of Bioscience and Biotechnology
- Applicants: Korea Research Institute of Bioscience and Biotechnology
- Inventors: Hyung Won RYU; Su Ui LEE; Sei-Ryang OH; Jae-Won LEE; Doo-Young KIM; Hyun-Jae JANG; Mun-Ock KIM; Seong Hun JEONG
- Web page: https://patentgrep.com/patent/US20240254155A1

## CPC

- C07H 15/256: Polyterpene radicals
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 36/21: Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
- A61P 11/06: Antiasthmatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07H 1/08: from natural products
- C07H 17/04: Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07J 53/00: Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, {including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class}
- C07J 63/00: Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- A61K 2236/33: involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K 2236/35: Extraction with lipophilic solvents, e.g. Hexane or petrol ether
- A61K 2236/55: Liquid-liquid separation; Phase separation
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

The present invention relates to a novel compound isolated from spinach, and a composition comprising same for preventing or treating inflammatory diseases, and, more particularly, to a novel medicagenic acid glycoside compound isolated from spinach, a preparation method therefor, and a composition comprising same for preventing or treating inflammatory diseases.

## Claims

### Claim 1

A compound represented by any one of the following formulae 1 to 6:
pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof or solvates thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is isolated from spinach.

### Claim 3 (depends on 1)

A method for preparing the compound of claim 1, comprising:
(a) extracting spinach with a solvent selected from the group consisting of water, organic solvents, subcritical fluids, supercritical fluids and mixtures thereof;
(b) fractionating the spinach extract by chromatography to obtain fractions; and
(c) isolating the compound from the fractions.

### Claim 4 (depends on 3)

The method of claim 3, wherein, in step (a), the organic solvent is selected from the group consisting of alcohol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane and petroleum ether having 1 to 6 carbon atoms.

### Claim 5 (depends on 3)

The method of claim 3, wherein, in step (b), the chromatography is sequentially developed according to a concentration gradient by using water and a non-polar solvent as mobile phases.

### Claim 6 (depends on 5)

The method of claim 5, wherein, in step (b), fractions fractionated from 20 to 100% (v/v) of a non-polar solvent aqueous solution are obtained.

### Claim 7 (depends on 1)

A pharmaceutical composition for preventing or treating inflammatory diseases, comprising as an active ingredient one or more selected from the group consisting of the compounds according to claim 1
pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof, and solvates thereof.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the inflammatory disease is selected from the group consisting of inflammatory respiratory disease, dermatitis, atopic dermatitis, allergy, psoriasis, bronchitis, ulcerative colitis, retinitis, uveitis, conjunctivitis, arthritis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, nephritis, nephritis, autoimmune pancreatitis, chronic pelvic inflammatory disease, endometritis, otitis media, cystitis, and chronic prostatitis.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the inflammatory respiratory disease is selected from the group consisting of asthma, pneumonia, acute lung injury, acute respiratory failure syndrome, chronic obstructive pulmonary disease, allergic rhinitis, bronchitis, pharyngitis, laryngitis, pharyngitis, and tonsillitis.

### Claim at position 10

-16. (canceled).

### Claim 17

A method of treating inflammatory diseases, comprising administering to a subject in need thereof an effective amount of a composition comprising as an active ingredient one or more selected from the group consisting of the compounds represented by any one of the following formulae 1 to 6:
pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof, and solvates thereof.
